Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 955 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 7 8 9 10  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. 2019-04-09
Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors 2019-04-04
Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden 2019-04-04
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors 2019-03-26
Cytena–SEVERAL: investment, 201903 financing round Series A €3m from HTGF + two private investors 2019-03-26
Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine 2019-03-26
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903–201908 acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Mobidiag–Consilium: public relations, 201902 service existent by CSC 2019-02-25
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
Samplix–EU (govt): grant, 201901– Horizon 2020 SME Instrument Program Grant €1.9m 2019-01-10
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
10x Genomics–Fidelity: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Fidelity 2019-01-07
10x Genomics–Meritech Capital: investment, 201901 financing round Series D extension totalling $35m incl existing + lead investor Meritech Capital 2019-01-07
10x Genomics–SEVERAL: investment, 201901 financing round Series D extension $35m led by Meritech Capital + incl Fidelity + Wells Fargo 2019-01-07
10x Genomics–Wells Fargo: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Wells Fargo 2019-01-07
Minervax–Novo Group: investment, 2018 investment €3.6m by Novo REPAIR Impact Fund 2018-12-31
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Spatial Transcriptomics–10x Genomics: investment, 201812 acquisition of Spatial by 10x Genomics 2018-12-10
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Aprea–SEVERAL: investment, 201812 financing round Series C €50m led by new investor Redmile Group 2018-12-02
Dispendix–Cellink: investment, 201811 acquisition €5m of Dispendix GmbH by Cellink AB 2018-11-30
BridgeBio–Leo Pharma: investment, 201811 acquisition minority stake in PellePharm Inc plus r+d funding + plus option to aquire PellePharm 2018-11-20
Symphogen–Thermo Fisher: mass spectrometer, 201810 supply Q Exactive Plus Orbitrap LC-MS/MS with BioPharma Option for biopharma QC 2018-10-29
Thermo Fisher–Symphogen: mass spectrometry, 201810– collab developm biopharma QC workflows using Q Exactive Plus Orbitrap LC-MS/MS system 2018-10-29
Galecto Biotech–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners 2018-10-26
Galecto Biotech–OrbiMed: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor OrbiMed 2018-10-26
Galecto Biotech–SEVERAL: investment, 201810 financing round Series C €79m co-led by Ysios Capital + OrbiMed 2018-10-26
Galecto Biotech–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital 2018-10-26
Euformatics–EU (govt): grant, 201810– H2020 grant €700k for participation in GEMMA project 2018-10-25
Milestone Pharmaceuticals–Forbion: investment, 201810 financing round private totalling $80m incl existing + co-investor Forbion 2018-10-25
Milestone Pharmaceuticals–Novo Group: investment, 201810 financing round private totalling $80m incl existing + co-investor Novo Holdings A/S 2018-10-25
Milestone Pharmaceuticals–SEVERAL: investment, 201810 financing round private $80m led by RTW Investments 2018-10-25
Zelluna–Image Box: public relations, 201810 supply service existent by Image Box PR 2018-10-24
Immunicum–SEVERAL: investment, 201810– capital increase SEK351m with 40.3m new shares at SEK8.5/share 2018-10-16
Rgenix–Novo Group: investment, 201810 financing round Series C totalling $40m incl existing + co-investor Novo Holdings AS 2018-10-09
Rgenix–SEVERAL: investment, 201810 financing round Series C $40m led by Lepu Medical + incl Novo Holdings + Sofinnova Partners et al 2018-10-09
Rgenix–Sofinnova: investment, 201810 financing round Series C totalling $40m incl existing + co-investor Sofinnova Partners 2018-10-09
Entasis Therapeutics–Novo Group: investment, 201809 IPO totalling $75m on Nasdaq incl $10m investment by Novo REPAIR Impact Fund 2018-09-25
Morphic–SEVERAL: investment, 201809 financing round Series B $80m co-led by Omega Funds + Novo Holdings 2018-09-25
Fluidigm–Visiopharm: image analysis software, 201809– collab co-marketing of Visiopharm s/w with Hyperion Imaging System 2018-09-10
Ilya Pharma–SEVERAL: investment, 201809 targted share issue €3m 2018-09-10
RSP Systems–SEVERAL: investment, 201809 financing round Series B 2nd closing €3.85m incl new investor Trumpf Venture GmbH 2018-09-10
RSP Systems–Trumpf: investment, 201809 financing round Series B 2nd closing totalling €3.85m incl new investor Trumpf Venture GmbH 2018-09-10
Polyphor–Novo Group: investment, 201809 capital increase CHF6.8m with 179k shares at CHF38/share sold to Novo REPAIR Impact Fund 2018-09-06
Polyphor–Novo Group: investment, 201809– project-based + royalty-bearing investment up to CHF4.7m based on milestones in OMPTA program by Novo REPAIR 2018-09-06
Visiopharm–ATP (DK): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK45m from new + lead investor ATP 2018-08-24
Visiopharm–CL David Foundation: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from new investor CL David Foundation 2018-08-24
Visiopharm–Denmark (govt): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK20m from new investor Danish Growth Fund 2018-08-24
Visiopharm–Northcap Venture Partners: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from existing investor Northcap 2018-08-24
Visiopharm–SEVERAL: investment, 201808 financing round DKK100m (€13.3m) led by new investor ATP 2018-08-24
Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance r+d small molecule drugs for diabetes + obesity Novo Nordisk 2018-08-22
Bavarian Nordic–PCI Biotech: PCI technology, 201808– collab research preclinical evaluation of integration of technologies from both companies 2018-08-20
Entasis Therapeutics–SEVERAL: investment, 201809 IPO $75m on Nasdaq 2018-08-17
Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk 2018-08-17
Bavarian Nordic–EU (govt): credit, 201808– EIB loan €30m to support construction + validation of vaccine manufacturing facility 2018-08-09
ReViral–Novo Group: investment, 201808 financing round Series B totalling $55m incl new + co-lead investor Novo Ventures 2018-08-01
ReViral–SEVERAL: investment, 201808 financing round Series B $55m co-lead by new investors New Leaf Venture Partners + Novo Ventures 2018-08-01
Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer 2018-07-31
SHS–SEVERAL: investment, 201807 first closing €90m of SHS V fund with target size of €150m 2018-07-20
Modus Therapeutics–Odlander Fredrikson: investment, 201807 financing round totalling SEK140m incl SEK60m from new + lead investor HealthCap 2018-07-13
Modus Therapeutics–SEVERAL: investment, 201807 financing round SEK140m incl SEK60m from HealthCap + conversion convertible notes by shareholders 2018-07-13
Genmab–Immatics: cancer immunotherapy, 201807– researc collab + excl license to targets for biospecific I-O drugs $54m upfront + $550m milestones 2018-07-12
IMMUNOMONITOR project–Biomax: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response to cancer vaccines 2018-07-05
IMMUNOMONITOR project–Enpicom: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response to cancer vaccines 2018-07-05
IMMUNOMONITOR project–EU (govt): grant, 201807– Eurostars grant €2m to develop clin validation for treatm response to cancer vaccines 2018-07-05
IMMUNOMONITOR project–OSE Immunotherapeutics: pharmacogenomics, 201807– collab project partner develop validation treatm response cancer vaccines 2018-07-05
IMMUNOMONITOR project–Ultimovacs: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response cancer vaccines 2018-07-05
IMMUNOMONITOR project–Univ Hamburg: pharmacogenomics, 201807– collab partner Eurostars in project develop validation treatm response cancer vaccines 2018-07-05
Immuneed–Ultimovacs: investment, 201807 acquisition NOK50.4m in cash + shares of TET Pharma cancer vaccine technology sub from Immuneed by Ultimovacs 2018-07-01
Ultimovacs–Immuneed: investment, 201807 acquisition 5.41% shareholding as part of compensation for sale of TET Pharma business to Ultimovacs 2018-07-01
JnJ–Medivir: antiviral, –201806 license for simeprevir to Janssen Pharmaceuticals Inc TERMINATED 6/18 2018-06-30
NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m 2018-06-28
ProZyme–Agilent: investment, 201806–201808 acquisition €na of ProZyme Inc by Agilent 2018-06-28
Onxeo–Nice & Green: investment, 201806–201903 equity line financing up to €5.4m with up to 4.7new shares 2018-06-15
RSP Systems–SEVERAL: investment, 201806 financing round Series B first closing €6.5m incl family offices + private investors 2018-06-11
Orphazyme–Centogene: biomarker discovery, 201805– collab service biomarkers for Gaucher disease clinical trial monitoring 2018-05-23
Novo Group–BioLamina: cell culture technology, 201805– collab using BioLaminins rec hum laminin cell culture matrices for cell therapies Novo Nordisk 2018-05-16
Recipharm–Hadassah (HMO): drug development services, 201805– collab combined offering of clinical + biological + chemical services Hadasit 2018-05-15
BioClin Therapeutics–ABP (NL): investment, 201805 financing round Series B extension totalling $20m incl new investor Inkef Capital 2018-05-09
BioClin Therapeutics–Sectoral Asset Management: investment, 201805 financing round Series B extension totalling $20m incl new investor Sectoral Asset 2018-05-09
BioClin Therapeutics–SEVERAL: investment, 201805 financing round Series B extenstion $20m from new investors Sectoral Asset + Inkef Capital 2018-05-09
Wilson Therapeutics–Alexion: investment, 201804–201805 cash tender offer SEK7.1b ($855m) with SEK232/share by Alexion 2018-04-11
PITBUL project–EU (govt): grant, 201803–2020 Horizon 2020 grant €3.8m to develop ultrafast PoC tuberculosis diagnostic platform 2018-03-24
NMD Pharma–ABP (NL): investment, 201803 financing round Series A totalling €38m incl new + lead investor Inkef Capital 2018-03-23
NMD Pharma–Lundbeck: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Lundbeckfonden Emerge 2018-03-23
NMD Pharma–Novo Group: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Novo Seeds 2018-03-23
next pagenext page 1 2 3 4 5 6 7 8 9 10  next pagenext page



Advertisement

Picture [iito] – Putting Information into Context 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75

» top